Bioresorbable Sirolimus-eluting scaﬀold in de Novo Coronary Artery Lesions — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Bioresorbable Sirolimus-eluting scaﬀold in de Novo Coronary Artery Lesions — Stella

Home/De Novo Stenosis/

View on ClinicalTrials.gov

Recruiting

Back to De Novo Stenosis trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Xijing Hospital, Xi'an, Shannxi

Key details

Sponsor

Xijing Hospital

Enrollment target

~2,000 participants

Started

December 2025

Primary completion

December 2030

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.